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BACKGROUND: Participants are showing great interest these days in obtaining the results of clinical trials. The aim of this study was to
assess patients’ uptake and understanding of the results of the trial in which they have participated and the impact of a letter offering
patients the possibility of consulting the trial results on a specific website.
METHODS: Breast cancer patients participating in a trial on the efficacy of Trastuzumab were randomly subdivided into an Internet
group (who received the letter of invitation) and a control group (who did not receive it). Among 115 HER2-positive women from
21 centres, 107 (93%) answered a self-administered questionnaire.
RESULTS:Most of the patients in both groups had access to the Internet (72.0%). The majority (97.2%) stated that receiving information
about the trial results would be useful, and the oncologist was the most frequently preferred information provider. The Internet
group’s declared uptake of the trial results was only slightly higher (47.1% vs 33.9%; P¼0.166); however, they understood the results
significantly more accurately (18.8% vs 5.6%; P¼0.039).
INTERPRETATION:Although Internet was not the respondents’ preferred source of information, the possibility of using this source slightly
increased the uptake and understanding of the results.
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Consistent evidence has become available that patients involved in
randomised clinical trials (RCTs) want to know about the results
despite their potentially negative emotional impact (Shalowitz and
Miller, 2008), but previous authors have emphasised the organisa-
tional difficulties involved in this information process. It requires
considerable resources, and contacting and informing the patients
is time consuming for physicians and nurses, especially as a long
gap often elapses after trials before the results are available.
Participants may therefore be rarely informed (Fernandez et al,
2003, 2004; Partridge et al, 2004).
Few studies have focused so far on participants’ preferred mode
of dissemination of trial results, or on the best methods of
diffusing this information while respecting patients’ autonomy.
The authors of a recent review of the literature (Shalowitz and
Miller, 2008) mentioned that participants often prefer to receive
the results in writing, but specified that participants in a trial on
the treatment of breast cancer preferred to be given the results by
their physicians (Partridge et al, 2003). In France, investigators are
legally obliged to inform participants about trial results, and the
French drug authority (AFSSAPS) plans to publish these results on
their website (https://icrepec.afssaps.fr/Public/apropos.php).
Making RCT results available on websites seems to be one of the
best solutions: it is an inexpensive method, which is easier to
organise than face-to-face consultations and gives patients the
opportunity to decline, as it requires their active participation.
The latter point is crucial, because some patients do not
want to know about the results, and this preference should be
respected (Shalowitz and Miller, 2008). However, not all cancer
patients use the Internet (Mancini et al, 2006), and information
obtained via this medium may be less understandable and more
emotionally disturbing because patients are unable to ask
questions (Partridge et al, 2009).
The aim of this study was to assess patients’ uptake and
understanding of the results of the trial in which they have
participated, and the impact of a letter offering patients the
possibility of consulting the trial results on a specific website.
MATERIALS AND METHODS
This study, which was approved by the French National
Committee on Personal Data and Privacy (CNIL), was carried
out at 21 specialised centres all over France between June 2008 and
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sMay 2009. Adult women with HER2-positive non-metastatic breast
cancer included in the FNCLCC-PACS04 clinical trial, the first
results of which (about the efficacy of Trastuzumab) were issued in
December 2007 (Spielmann et al, 2009), were included in the study.
A patient’s leaflet was then written by a medical journalist with the
help of expert patients from the French Cancer League, and was
made available only on a password-protected website (http://
www.fnclcc.fr/doc/pdf/info_patients/prive/trait-union-no13.pdf
(User¼BECT; Password¼PACS04)) (see Supplementary online
material). At the time of the trial, participants were not told that
they would be able to consult the results.
Among the 166 women contacted by mail by their oncologist,
115 (69.3%) agreed to participate and answered a two-page
baseline questionnaire. These 115 women were subdivided into
two groups by the ‘off-site’ coordinators (UMR912) using simple
random sampling methods with a concealed allocation. The
Internet group (n¼55) received a letter stating that the trial
results were available on the password-protected website, while the
control group received no letters (n¼60). At 6 months after
consenting, all the women were mailed a second self-administered
questionnaire; 51 (92.7%) and 56 (93.3%) women, respectively, in
the Internet and control groups responded.
Medical characteristics were collected from the FNCLCC-
PACS04 trial database. Sociodemographic data, ‘extent of informa-
tion desired’ (Zwaenepoel et al, 2006), and perception of the
usefulness of being informed about the trial results were
ascertained in the baseline questionnaire.
In the second questionnaire, questions were asked (see
Supplementary online material) about the participants’ expecta-
tions about the trial results, their preferences about the mode of
disclosure, their declared uptake of the results and their under-
standing of the outcome of this trial, that is, the fact that
Trastuzumab did not significantly decrease the risk of relapse
4 years after diagnosis in the FNCLCC-PACS04 trial. The question
as to whether patients discussed the results with their next of kin
was also addressed.
Statistical tests (SPSS 15.0) were performed between
the continuous (Student’s t-test) and categorical characteristics
(w
2 or Fisher’s exact test) of the two groups. P-values below 0.05
were taken to be statistically significant.
RESULTS
The two randomised groups did not differ in terms of their
sociodemographics, Internet access or Trastuzumab allocation.
Both groups felt a priori that informing participants about the
outcome of clinical trials would be useful (Table 1). Both groups
stated alike (P¼0.509) that access to clinical trial results should be
systematic (45.7%), at either the patient’s request (41.0%) or the
physician’s discretion (13.3%). Expectations about the results were
also similar in both groups: knowing whether the trial yielded
useful results (82.2%; P¼0.633), understanding the treatment
received (20.6%; P¼0.468), and understanding clinical trials
(9.3%; P¼0.745).
Similar preferences about how patients should be informed
about clinical trial results and by whom were expressed
by both groups, except that Internet was more frequently
qualified as ‘perfectly suitable’ by the Internet group (43.5% vs
17.6%; P¼0.006; Figure 1). However, being informed via
Internet was less frequently preferred than a face-to-face
consultation or a mailed letter. Oncologists, followed by trial
investigators, were the participants’ preferred providers of trial
result information.
Table 1 Characteristics of the women studied
Internet group (n¼51) Control group (n¼56) Total (n¼107)
n%n% n % P value
Marital status 0.530
Married 40 78.4 41 73.2 81 75.7
Education 0.283
‘Baccalaure ´at’ or lower level 33 67.3 32 57.1 65 61.9
Occupational activity 0.663
Yes 24 47.1 24 42.9 48 44.9
Economic difficulties 0.623
Not at all 24 47.1 28 51.9 52 49.5
Internet access 0.244
Yes 34 66.7 43 76.8 77 72.0
Health-related Internet use 0.400
Yes 25 49.0 32 57.1 57 53.3
Usefulness of clinical trial results disclosure to participants 1.000
Useful–very useful 50 98.0 54 96.4 104 97.2
Trastuzumab arm in PACS04 trial 0.585
Yes 30 58.8 30 53.6 60 56.1
M SD M SD M SD
Age 57.7 8.0 55.7 9.8 56.7 9.0 0.248
Number of children 1.9 1.0 2.0 1.1 2.0 1.0 0.568
Distance from oncological centre (km) 55.5 56.9 43.2 40.5 49.2 49.3 0.226
Time since PACS04 trial inclusion (years) 6.0 0.9 6.2 1.0 6.1 0.9 0.298
‘Extent of information desired’ score 19.6 3.6 18.8 3.8 19.1 3.7 0.311
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sThe declared uptake of the clinical trial results was non-
significantly higher in the Internet group (47.1%) than in the
control group (33.9%; P¼0.166). Multiple sources of uptake were
declared by 23.5% of the Internet group, as compared with 10.7%
of the control group (P¼0.077). These sources were a website
(33.3% vs 8.9% in the Internet vs control group; P¼0.002), the
oncologist (29.4% vs 28.6%; P¼0.924), and other sources (11.8%
vs 8.9%; P¼0.629). Among the 43 patients who declared having
had access to the results, 22 (51.2%) had discussed these results
with a close relative and 5 others (11.6%) planned to do so. Open
commentaries showed that the results were often discussed with
the spouse and other relatives, the oncologist, the general
practitioner, and other patients. Talking about the results was
said to be easier when they were perceived as positive. Negative
results were also discussed, however, in order to obtain
reassurance about their personal significance. One patient’s next
of kin were surprised by the randomisation procedure. Two
patients reported a lack of communication because the cancer was
‘over’ and was no longer a topic of discussion in the family.
The trial results were better understood by the Internet group
(18.8%) than by the control group (5.6%; P¼0.039). Among the
patients who declared they had obtained the results via a website,
37.5% of the Internet group understood the results fairly well,
which was not the case in the control group (0%; P¼0.262).
DISCUSSION
This is the first randomised study in which participants’ uptake of
the results of a RCT has been measured.
First, a fairly high proportion of women declared that they had
consulted the results of the trial in comparison with what health
professionals’ statements might suggest (Partridge et al, 2004). As
Trastuzumab was already being used to treat metastatic breast
cancer, a lot of information about this drug was circulating on
Internet, and some confusion about the specific results of the
FNCLCC-PACS04 trial may therefore have occurred. As uptake of
results was self-declared, it was probably over-estimated by the
patients, but presumably to the same extent in both groups. This
would be consistent with some patients’ poor understanding of
the results, which may have been due to confusion between
information about the effectiveness of Trastuzumab in general and
the specific results of the FNCLCC-PACS04 trial. It can be difficult
for health practitioners and patients to find out exactly what they
want to know about drugs on Internet when these drugs are
already being used for other indications.
Second, it was previously reported that 90% of the participants
in a phase II trial giving negative results chose to receive the results
in response to a letter describing the early closure of the study
and proposing to divulge the results (Partridge et al, 2005). The
comparatively low uptake observed in the Internet group could not
be entirely attributable to the lack of availability of Internet or the
fact that little use of Internet was made for health-related purposes.
Some patients declared spontaneously in their open comments
that if they had known that the trial results had become available,
they would have asked for an appointment with their oncologist.
This would be consistent with our findings showing that the
preferred mode of disclosure on the whole was consultation with
the oncologist. However, the Internet method of disclosure was
preferred more frequently by those who had actually used this
method. Some performance bias may have occurred here, but these
results also possibly suggest that these participants were favour-
ably impressed by this method. This is consistent with studies
showing that most patients were comfortable with receiving
written results by impersonal means, especially if a two-step
procedure is used for this purpose (Partridge et al, 2005, 2009;
Fernandez et al, 2009). Although it was reported in a previous
study (Fernandez et al, 2009) that websites are not patients’
favourite way of receiving the results, this method was acceptable
to some patients. Therefore, this could be one of the modes of
disclosure proposed to patients, as suggested by Partridge and
Winer (2009), as it enables each patient to choose the most
appropriate mode.
Third, to assess the effects of website information with greater
power (80%), four times more patients would have to be included.
Recruiting patients for this study was particularly difficult: we had
to find an RCT of which the results had not been issued at the time
of the study; the patients with HER2-positive receptors included
here amounted to less than 20% of the total number of patients
participating at 44 centres in the FNCLCC-PACS04 trial. In
addition, about 20% of the participants could no longer be
reached 6 years after the RCT because they were not in good health
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Figure 1 Patients’ preferences about trial result disclosure.
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sor were no longer alive. Despite this main limitation, the strengths
of this study were the nation-wide recruitment and the fact that
this is the first time, to our knowledge, that a standard situation
has been compared with an experiment designed to enhance the
uptake of results. In addition, the second point that was objectively
assessed showed that the use of Internet significantly improved
patients’ understanding of the trial results despite the low
statistical power. In another study, 69% of the participants who
were mailed the results interpreted them correctly (Partridge et al,
2009). The poor understanding observed here may have been
due to the existence of discrepancies between the present
results (showing the lack of effectiveness of Trastuzumab) and
those previously presented in the literature and could have arisen
from the need to specify more clearly the question addressed here
(the effect of 18-month Herceptin treatment after chemotherapy
on the 4-year risk of cancer progression). The poor understanding
shown by some participants might also be attributable to their low
levels of literacy and their lack of familiarity with medical
language.
This is the first attempt to assess an Internet-based method of
informing patients. The results obtained show that this method
only slightly improved the patients’ understanding and non-
significantly improved the declared rate of consultation of the RCT
results. The usefulness of obtaining RCT results declared by the
majority of the patients contrasted with the rather low rate of
uptake declared by those in the Internet group. This question
needs to be investigated more closely in larger samples, as well as
using qualitative methods to determine the best way of meeting
participants’ need for information about the results of trials.
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